SMT201700105B - Nuove composizioni per prevenire e/o trattare disturbi degenerativi del sistema nervoso centrale - Google Patents

Nuove composizioni per prevenire e/o trattare disturbi degenerativi del sistema nervoso centrale

Info

Publication number: SMT201700105B
Authority: SM; San Marino
Prior art keywords: prevent; nervous system; central nervous; new compositions; degenerative disorders
Prior art date: 2009-10-19

Application number

SM201700105T

Other languages

English (en)

Inventor

Robert Boyd

Gary Lee

Philip Rybczynski

Original Assignee

Amicus Therapeutics Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-10-19

Filing date

2017-02-16

Publication date

2017-03-08

2017-02-16 Application filed by Amicus Therapeutics Inc filed Critical Amicus Therapeutics Inc

2017-03-08 Publication of SMT201700105B publication Critical patent/SMT201700105B/it

Links

210000003169 central nervous system Anatomy 0.000 title 1
230000003412 degenerative effect Effects 0.000 title 1
239000000203 mixture Substances 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
- C07D211/96—Sulfur atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Biomedical Technology (AREA)
Engineering & Computer Science (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Psychology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Hydrogenated Pyridines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Plural Heterocyclic Compounds (AREA)

SM201700105T 2009-10-19 2017-02-16 Nuove composizioni per prevenire e/o trattare disturbi degenerativi del sistema nervoso centrale SMT201700105B (it)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US25280309P	2009-10-19	2009-10-19

Publications (1)

Publication Number	Publication Date
SMT201700105B true SMT201700105B (it)	2017-03-08

Family

ID=43879775

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
SM20170105T SMT201700105T1 (it)	2009-10-19	2010-10-05	Nuove composizioni per prevenire e/o trattare disturbi degenerativi del sistema nervoso centrale
SM201700105T SMT201700105B (it)	2009-10-19	2017-02-16	Nuove composizioni per prevenire e/o trattare disturbi degenerativi del sistema nervoso centrale

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
SM20170105T SMT201700105T1 (it)	2009-10-19	2010-10-05	Nuove composizioni per prevenire e/o trattare disturbi degenerativi del sistema nervoso centrale

Country Status (26)

Country	Link
US (4)	US8604206B2 (it)
EP (2)	EP2490532B1 (it)
JP (2)	JP5805649B2 (it)
KR (3)	KR101813988B1 (it)
CN (2)	CN105367485B (it)
AR (1)	AR078606A1 (it)
AU (3)	AU2010308396B2 (it)
BR (1)	BR112012009121A2 (it)
CA (1)	CA2778348C (it)
CY (1)	CY1118966T1 (it)
DK (1)	DK2490532T3 (it)
ES (2)	ES2814178T3 (it)
HR (1)	HRP20170236T1 (it)
HU (1)	HUE033116T2 (it)
IL (1)	IL219160B (it)
LT (1)	LT2490532T (it)
MX (2)	MX340807B (it)
PL (1)	PL2490532T3 (it)
PT (1)	PT2490532T (it)
RS (1)	RS55679B1 (it)
RU (2)	RU2015147509A (it)
SG (1)	SG10201507159XA (it)
SI (1)	SI2490532T1 (it)
SM (2)	SMT201700105T1 (it)
TW (1)	TWI642434B (it)
WO (1)	WO2011049736A1 (it)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PT2995306T (pt)	2009-10-19	2019-03-29	Amicus Therapeutics Inc	Novas composições para prevenção e/ou tratamento de disfunções de armazenamento lisossomal
DK2490532T3 (en)	2009-10-19	2017-02-27	Amicus Therapeutics Inc	Hitherto UNKNOWN COMPOSITIONS FOR PREVENTION AND / OR TREATMENT OF DEGENERATIVE DISORDERS IN THE CENTRAL Nervous System
EP2591823A1 (en) *	2011-11-11	2013-05-15	Biologische Heilmittel Heel GmbH	Composition for treating or preventing neurodegenerative disorders
CA2868459A1 (en)	2012-03-27	2013-10-03	Amicus Therapeutics, Inc.	Polymorphs of (3r,4r,5s)-5-(difluoromethyl)piperidine-3,4-diol fumarate and uses thereof
EP3087056A4 (en) *	2013-12-23	2017-07-19	Alectos Therapeutics Inc.	Glucocerebrosidase modulators and uses thereof
US10179128B2 (en)	2015-08-31	2019-01-15	Amicus Therapeutics, Inc.	Regimens for treating and preventing lysosomal disorders and degenerative disorders of the central nervous system
WO2018200618A1 (en)	2017-04-25	2018-11-01	Amicus Therapeutics, Inc.	Novel compositions for preventing and/or treating degenerative disorders of the central nervous system and/or lysosomal storage disorders
RU2676956C1 (ru) *	2017-08-25	2019-01-11	Общество с ограниченной ответственностью "Международный Биотехнологический Центр "Генериум"	Антитела для связывания имиглюцеразы и их применение в аффинной хроматографии
KR101991276B1 (ko)	2018-01-19	2019-06-21	전남대학교산학협력단	신규 균주 페니실리움 아쿠아티쿰 및 이를 이용한 퇴행성 뇌질환 치료제
US20220184185A1 (en)	2018-07-25	2022-06-16	Modernatx, Inc.	Mrna based enzyme replacement therapy combined with a pharmacological chaperone for the treatment of lysosomal storage disorders
EP3962492A4 (en) *	2019-04-29	2023-05-31	Thomas Jefferson University	METHODS OF TREATMENT OF NEURODEGENERATIVE DISEASES
US20240262832A1 (en) *	2021-04-30	2024-08-08	Vanqua Bio, Inc.	Small molecule modulators of glucocerebrosidase activity and uses thereof
WO2022232360A1 (en) *	2021-04-30	2022-11-03	Vanqua Bio, Inc.	Small molecule modulators of glucocerebrosidase activity and uses thereof
WO2024163532A1 (en) *	2023-01-31	2024-08-08	Bioeutectics Corporation	Use of additives (adjuvants, anti freezing agents, antimicrobial and antioxidants) in natural deep eutectic solvents and mixtures

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4407957A (en)	1981-03-13	1983-10-04	Damon Corporation	Reversible microencapsulation of a core material
SG47470A1 (en)	1991-04-25	1998-04-17	Univ Brown Res Found	Implantable biocompatible immunoisolatory vehicle for delivery of a selected therapeutic products
US5383851A (en)	1992-07-24	1995-01-24	Bioject Inc.	Needleless hypodermic injection device
US5569189A (en)	1992-09-28	1996-10-29	Equidyne Systems, Inc.	hypodermic jet injector
ATE220327T1 (de)	1992-09-29	2002-07-15	Inhale Therapeutic Syst	Pulmonale abgabe von aktiven fragmenten des parathormons
AU1890295A (en) *	1994-03-09	1995-09-25	Novo Nordisk A/S	Piperidines and pyrrolidines
US5863903A (en) *	1994-03-09	1999-01-26	Novo Nordisk A/S	Use of hydroxy alkyl piperidine and pyrrolidine compounds to treat diabetes
FR2718357B1 (fr)	1994-04-06	1997-10-03	Defarges Alain Moreau	Perfectionnements apportés à un dispositif d'injection par jet sans aiguille.
US5599302A (en)	1995-01-09	1997-02-04	Medi-Ject Corporation	Medical injection system and method, gas spring thereof and launching device using gas spring
US5780014A (en)	1995-04-14	1998-07-14	Inhale Therapeutic Systems	Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin
US5654007A (en)	1995-06-07	1997-08-05	Inhale Therapeutic Systems	Methods and system for processing dispersible fine powders
TW498067B (en) *	1996-07-19	2002-08-11	Hoffmann La Roche	4-hydroxy-piperidine derivatives
US6274597B1 (en) *	1998-06-01	2001-08-14	Mount Sinai School Of Medicine Of New York University	Method of enhancing lysosomal α-Galactosidase A
JP2006507359A (ja) *	2002-10-28	2006-03-02	ノボ・ノルデイスク・エー／エス	心循環器疾患の治療のためのグリコーゲンホスホリラーゼ阻害剤の使用
US20040082641A1 (en) *	2002-10-28	2004-04-29	Rytved Klaus Asger	Use of glycogen phosphorylase inhibitors for treatment of cardiovascular diseases
US7446098B2 (en)	2003-02-18	2008-11-04	Mount Sinai School Of Medicine Of New York University	Combination therapy for treating protein deficiencies
US20070270350A1 (en) *	2003-12-23	2007-11-22	Musc Foundation For Research Development	Methods and Compositions for the Prevention and Treatment of Inflammatory Diseases or Conditions
ES2364586T3 (es) *	2006-05-24	2011-09-07	Amicus Therapeutics, Inc.	Sal tartrato de isofagomina y métodos de uso.
US7501439B2 (en) *	2006-05-24	2009-03-10	Amicus Therapeutics, Inc.	Tartrate salt of isofagomine and methods of use
ATE555788T1 (de) *	2006-06-23	2012-05-15	Amicus Therapeutics Inc	Verfahren zur behandlung neurologischer erkrankungen mittels verstärkung der beta - glucocerebrosidaseaktivität
WO2008134628A2 (en)	2007-04-26	2008-11-06	Amicus Therapeutics, Inc.	Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
WO2010015816A2 (en)	2008-08-06	2010-02-11	Summit Corporation Plc	Treatment of lysosomal storage disorders and other proteostatic diseases
BRPI1010517A2 (pt)	2009-04-09	2017-01-31	Amicus Therapeutics Inc	métodos para prevenção e/ou tratamento de doenças de armazenamento lisossomal
CA2758187C (en) *	2009-04-09	2017-03-07	Robert Boyd	Methods for preventing and/or treating degenerative disorders of the central nervous system
PT2995306T (pt)	2009-10-19	2019-03-29	Amicus Therapeutics Inc	Novas composições para prevenção e/ou tratamento de disfunções de armazenamento lisossomal
DK2490532T3 (en) *	2009-10-19	2017-02-27	Amicus Therapeutics Inc	Hitherto UNKNOWN COMPOSITIONS FOR PREVENTION AND / OR TREATMENT OF DEGENERATIVE DISORDERS IN THE CENTRAL Nervous System
JP6061677B2 (ja) *	2009-10-19	2017-01-18	アミカスセラピューティックスインコーポレイテッド	薬理シャペロンを用いてガングリオシドの活性を増大させて、アルツハイマー病を治療するための方法
KR102023720B1 (ko)	2012-09-03	2019-09-20	엘지이노텍 주식회사	보이스 코일 모터

2010
- 2010-10-05 DK DK10825396.4T patent/DK2490532T3/en active
- 2010-10-05 RU RU2015147509A patent/RU2015147509A/ru unknown
- 2010-10-05 JP JP2012535221A patent/JP5805649B2/ja active Active
- 2010-10-05 MX MX2012004548A patent/MX340807B/es active IP Right Grant
- 2010-10-05 KR KR1020177022493A patent/KR101813988B1/ko not_active Expired - Fee Related
- 2010-10-05 WO PCT/US2010/051447 patent/WO2011049736A1/en not_active Ceased
- 2010-10-05 RS RS20170153A patent/RS55679B1/sr unknown
- 2010-10-05 SI SI201031401A patent/SI2490532T1/sl unknown
- 2010-10-05 CN CN201510783936.0A patent/CN105367485B/zh not_active Expired - Fee Related
- 2010-10-05 CA CA2778348A patent/CA2778348C/en active Active
- 2010-10-05 PT PT108253964T patent/PT2490532T/pt unknown
- 2010-10-05 HU HUE10825396A patent/HUE033116T2/en unknown
- 2010-10-05 BR BR112012009121A patent/BR112012009121A2/pt not_active Application Discontinuation
- 2010-10-05 ES ES16191218T patent/ES2814178T3/es active Active
- 2010-10-05 EP EP10825396.4A patent/EP2490532B1/en active Active
- 2010-10-05 RU RU2012120759/04A patent/RU2581058C2/ru active
- 2010-10-05 PL PL10825396T patent/PL2490532T3/pl unknown
- 2010-10-05 HR HRP20170236TT patent/HRP20170236T1/hr unknown
- 2010-10-05 KR KR1020127012936A patent/KR101769396B1/ko not_active Expired - Fee Related
- 2010-10-05 ES ES10825396.4T patent/ES2617192T3/es active Active
- 2010-10-05 SG SG10201507159XA patent/SG10201507159XA/en unknown
- 2010-10-05 EP EP16191218.3A patent/EP3143875B1/en active Active
- 2010-10-05 LT LTEP10825396.4T patent/LT2490532T/lt unknown
- 2010-10-05 SM SM20170105T patent/SMT201700105T1/it unknown
- 2010-10-05 US US12/898,112 patent/US8604206B2/en active Active
- 2010-10-05 AU AU2010308396A patent/AU2010308396B2/en not_active Ceased
- 2010-10-05 KR KR1020177037220A patent/KR101880411B1/ko not_active Expired - Fee Related
- 2010-10-05 CN CN2010800566279A patent/CN102655747A/zh active Pending
- 2010-10-05 MX MX2016000153A patent/MX368459B/es unknown
- 2010-10-12 AR ARP100103715A patent/AR078606A1/es unknown
- 2010-10-12 TW TW099134782A patent/TWI642434B/zh not_active IP Right Cessation
2012
- 2012-04-15 IL IL219160A patent/IL219160B/en not_active IP Right Cessation
2013
- 2013-11-19 US US14/084,131 patent/US9409862B2/en active Active
2015
- 2015-03-30 JP JP2015069784A patent/JP6258245B2/ja active Active
2016
- 2016-06-08 AU AU2016203817A patent/AU2016203817B2/en not_active Ceased
- 2016-07-22 US US15/217,217 patent/US20160326114A1/en not_active Abandoned
2017
- 2017-02-16 SM SM201700105T patent/SMT201700105B/it unknown
- 2017-02-22 CY CY20171100240T patent/CY1118966T1/el unknown
- 2017-12-07 AU AU2017272296A patent/AU2017272296B2/en not_active Ceased
2018
- 2018-06-01 US US15/995,813 patent/US10421724B2/en active Active

Also Published As

Publication number	Publication date
AU2016203817A1 (en)	2016-06-30
WO2011049736A1 (en)	2011-04-28
PT2490532T (pt)	2017-02-23
US20140080871A1 (en)	2014-03-20
EP2490532B1 (en)	2016-11-23
PL2490532T3 (pl)	2017-05-31
KR101769396B1 (ko)	2017-08-18
CN105367485B (zh)	2018-04-17
KR20170096220A (ko)	2017-08-23
US10421724B2 (en)	2019-09-24
JP6258245B2 (ja)	2018-01-10
MX368459B (es)	2019-10-03
EP2490532A4 (en)	2013-06-12
BR112012009121A2 (pt)	2017-08-29
US20160326114A1 (en)	2016-11-10
TWI642434B (zh)	2018-12-01
CA2778348A1 (en)	2011-04-28
AU2017272296B2 (en)	2019-07-11
EP2490532A1 (en)	2012-08-29
RS55679B1 (sr)	2017-07-31
US20110092541A1 (en)	2011-04-21
ES2814178T3 (es)	2021-03-26
US9409862B2 (en)	2016-08-09
KR101880411B1 (ko)	2018-07-19
SG10201507159XA (en)	2015-10-29
AU2016203817B2 (en)	2017-09-07
SMT201700105T1 (it)	2017-03-08
CN105367485A (zh)	2016-03-02
JP2015157822A (ja)	2015-09-03
HK1219724A1 (zh)	2017-04-13
HUE033116T2 (en)	2017-11-28
JP2013508366A (ja)	2013-03-07
MX340807B (es)	2016-07-27
US8604206B2 (en)	2013-12-10
IL219160B (en)	2018-12-31
JP5805649B2 (ja)	2015-11-04
CY1118966T1 (el)	2018-01-10
KR101813988B1 (ko)	2018-01-02
SI2490532T1 (sl)	2017-03-31
TW201116279A (en)	2011-05-16
AU2010308396B2 (en)	2016-04-28
AU2017272296A1 (en)	2018-01-25
RU2581058C2 (ru)	2016-04-10
EP3143875A1 (en)	2017-03-22
RU2015147509A (ru)	2019-01-14
LT2490532T (lt)	2017-03-27
MX2012004548A (es)	2012-07-04
CA2778348C (en)	2022-08-23
DK2490532T3 (en)	2017-02-27
KR20120104549A (ko)	2012-09-21
ES2617192T3 (es)	2017-06-15
IL219160A0 (en)	2012-06-28
US20180273474A1 (en)	2018-09-27
EP3143875B1 (en)	2020-05-27
KR20180001588A (ko)	2018-01-04
AU2010308396A1 (en)	2012-05-03
HRP20170236T1 (hr)	2017-04-07
CN102655747A (zh)	2012-09-05
AR078606A1 (es)	2011-11-23
RU2012120759A (ru)	2013-11-27

Publication	Publication Date	Title
SMT201500280B (it)	2016-01-08	Nuove composizioni per prevenire e/o trattare disturbi da accumulo lisosomiale
IL219160A0 (en)	2012-06-28	Novel compositions for preventing and/or treating degenerative disorders of the central nervous system
EP2552433A4 (en)	2013-11-06	COMPOSITIONS AND METHODS OF TREATING SOMATOSENSORY DISEASES
SI2464362T1 (sl)	2020-02-28	Probiotični pripravek za preprečevanje ali zdravljenje pasjih gastrointestinalnih motenj
HRP20160598T1 (hr)	2016-07-29	Bakterijski sastavi za prevenciju i liječenje degenerativne bolesti
IL239355A0 (en)	2015-07-30	Compositions of gamma-hydroxybutyrate and their use in the treatment of disorders
CL2012000487A1 (es)	2012-08-31	Composicion que comprende bifidobacterium longum baa-999 para tratar y/o prevenir trastornos gi funcionales.
SMT201600055B (it)	2016-04-29	Composizione farmaceutica per il trattamento o la prevenzione del glaucoma
DK2451796T3 (da)	2013-07-29	Tofaanaloger til behandling af dermatologiske lidelser eller tilstande
PL2504005T3 (pl)	2014-03-31	Zastosowanie pochodnych 1,3-difenyloprop-2-en-1-onu do leczenia zaburzeń wątroby
MX364173B (es)	2019-04-15	Compuestos, composiciones y metodos para proteger la salud cerebral en trastornos neurodegenerativos.
MX2012004078A (es)	2012-07-25	Compuestos y composiciones como moduladores de la actividad de gpr119.
IL225239A0 (en)	2013-06-27	Compounds for the treatment of acne and related diseases
IL215584A0 (en)	2011-12-29	Methods for preventing and/or treating degenerative disorders of the central nervous system
EP2429530A4 (en)	2012-10-31	METHOD AND COMPOSITIONS FOR TREATING DEGENERATIVE AND ISCHEMIC ILLNESSES
PL2437742T3 (pl)	2015-03-31	Nowe kompozycje do leczenia cmt i pokrewnych zaburzeń
PT2501234T (pt)	2017-12-13	Métodos e composições para o tratamento de sintomas associados com distúrbios de stress pós-traumático utilizando ciclobenzaprina
SMT201900015T1 (it)	2019-02-28	Medicamento per uso topico a base di acido ialuronico solfatato per il trattamento dei coaguli di fibrina e dei trombi
ZA201200016B (en)	2012-09-26	Topical micro-emulsion for the treatment of rheumatic disorders
GB2495885B (en)	2017-11-22	Combination pharmaceutical composition and methods of treating genitourinary system disorders
BRPI0909628A2 (pt)	2015-09-22	compostos de azaindol para o tratamento de distúrbios do sistema nervosos central
WO2011014520A3 (en)	2011-06-23	Compounds and compositions as modulators of gpr119 activity
HU0900231D0 (en)	2009-06-29	Compositions for the treatment of allergic disorders
EP2578206A4 (en)	2013-11-27	PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DISORDERS OF THE LOWER PART OF THE UROGENITAL SYSTEM
CL2011003050A1 (es)	2012-06-15	Compuestos derivados de 17beta-alquil-17alfa-oxi-estratrienos sustituidos; compuestos intermediarios derivados de oxitrienos; composicion farmaceutica; utiles en el tratamiento de trastornos dependientes del estrogeno.